Mr. Dean Slagel serves as an Investor Director of Haemostatix Ltd. Mr. Slagel serves as Managing Director of Esperante Ventures. Mr. Slagel established Esperante Ventures' operations in late 2003 and is responsible for its eight portfolio investments in the United States, United Kingdom, France and Germany to date. He has 23 years of biopharmaceutical industry and venture investing experience. He worked global marketing management role at Tillotts Pharma for 4 years. Mr. Slagel has over 17 years of pharmaceutical and biotechnology industry experience earned across four countries to Esperante. He spent 10 years with Ferring in the UK, France and Denmark, moving from regional operations to global business development and became Global Business Development Director in 2000. Mr. Slagel joined Ferring in 1995, moving from regional management to Global Business Development, becoming the Global Business Development Director in 2000. He was responsible for two significant international licensing deals. Mr. Slagel serves as a Director of Atox Bio Inc., Haemostatix, UroSens Ltd, Altacor, Canbex Therapeutics and TheRyte. He serves as Non-Executive Director of Altacor Limited. He has been a Director of Cara Therapeutics, Inc., since June, 2005. He served as a Non-Executive Director of Arquer Diagnostics Ltd until March 31, 2016. He served as Director of Novacta Biosystems Limited. He holds an M.B.A. from the ENPC School of Management in Paris.

 Opthamolgical Works